Directory Genopole®
LABORATORIES INFRASTRUCTURE ENTERPRISES
JUNE 2009
Contents

- Genopole®’s missions 04
- Genopole® projects 06
- Genopole® teams at your service 08
- Genopole® Research 09
- Genopole® Enterprises 10
- The G1J Ile-de-France seed fund 11
- The Genopole®-Medicen European Office 12
- Genopole® Global Infrastructure and Platforms 13
- Genopole® International 14
- Genopole® Cluster Engineering 15
- Genopole® Communication 16
- Genopole® Real Estate 17
- The Biopark 18
- Laboratories 19
- Infrastructure 43
- Enterprises 63
- Index of laboratories, enterprises and infrastructure 134
- Index of contacts 135
REINFORCING NEW RESEARCH THEMES AND FOSTERING THE GROWTH OF BIOTECHNOLOGY

THE BIOPARK - A PLACE FOR INNOVATION

- 20 academic laboratories
- 69 biotech companies
- 19 shared-access technology platforms and facilities
- €208 million in funds raised by Genopole® portfolio companies
- 670 patents filed by Genopole® portfolio companies
- 28 molecules or biotherapies, from the regulatory preclinical phase through to market launch
- 87,298 m² of real estate
- 2,293 direct jobs

FRANCE’S LEADING BIOPARK DEDICATED TO BIOTECH AND BIOTHERAPEUTICS

Genopole® was founded in Evry (in the Essonne county, just south of Paris) in 1998 on the initiative of the French government, the local authorities and the French Muscular Dystrophy Association (AFM). At that time, the concept of grouping together academic labs, biotech companies and high-level teaching and training skills on the same site was very novel for France.

Genopole®’s goal is to promote research excellence in the life sciences and to catalyze the creation of biotech companies, in order to keep France up with the leaders in a highly competitive international scientific and industrial environment.

Eleven years on, the Genopole® biopark has confirmed its position as a key French player in the field of biotherapies and biotechnology.

TRANSFORMING SCIENTIFIC PROGRESS INTO INNOVATIVE THERAPIES

As a key economic stakeholder in the life science sector, Genopole® brings together the skills and resources needed to achieve its objectives: fostering research, promoting drug-focused innovation and transferring technology to industry.

A MULTIDISCIPLINARY SCIENCE CAMPUS

As France’s leading biopark, Genopole® participates actively in the latest trends and developments in life science research. These notably include therapeutic approaches for rare genetic diseases (such as muscular dystrophies and cystic fibrosis) and degenerative diseases (such as type II diabetes, myocardial infarction, Parkinson’s disease and Alzheimer’s disease).

With a solid fundamental science base in genomics and post-genomics, Genopole® specializes in proteomics, metabolomics, systems biology and synthetic biology.

...AND A BIOPARK FOR HI-TECH COMPANIES

Genopole’s® highly diversified set of corporate members includes innovative drug discovery firms, diagnostics manufacturers and scientific & medical instrumentation suppliers, together with businesses in the environmental and agricultural sectors. A number of R&D service companies provide drug development support. A dedicated company incubation and start-up team offers managerial assistance (strategy), resources (start-up facilities) and financial support (business development and finance), in close collaboration with other private- and public-sector business support and funding organizations.
A CLUSTER THAT LOOKS TO THE FUTURE

Genopole®’s objective is to become a biocluster with global visibility within the next 10 years.

- thanks to its research firepower (notably in human embryonic & somatic stem cell research and gene therapy), Genopole® is building on its foundations in regenerative medicine.

- the availability of a wide range of production technologies and services are helping to make Genopole® a centre of excellence in biomanufacturing.

In addition to the production of therapeutics, Genopole® is also focusing efforts on the environment – notably by developing new-generation biofuels and building biomanufacturing units capable of producing enzymes (for novel depollution systems and green waste systems) and high-added-value organic compounds via bioconversion.

A FAST-GROWING TEACHING CLUSTER

The University of Evry-Val d’Essonne (UEVE) hosts more than 10,000 students and offers over 160 multidisciplinary undergraduate and postgraduate courses, in close collaboration with Genopole®.

The UEVE also has acknowledged expertise in genomics/post-genomics research and the applications of this knowledge in healthcare and the environment. The university’s Biology Department comprises fifteen research groups (most of which are joint units with the CNRS, the INSERM, INRA or CEA national research institutes).

The prime fields of research are biotherapies, stem cells, genomics, post-genomics, bio-informatics, biomaterials and modeling & mathematics applied to biology – themes which have been grouped together under the heading «systems biology» and, more recently, «synthetic biology».

In addition to this main focus, the UEVE is also developing its research efforts in other areas: physical science & engineering, finance, employment, enterprise and public-sector labor policies.

A HIGH-QUALITY SCIENTIFIC AND TECHNOLOGICAL ENVIRONMENT

The Paris Ile-de-France region is home to no fewer that 300 private- and academic research laboratories and about 200 biotech companies* (accounting for 50% of the French total!). The Essonne county is situated at the heart of this region and hosts between 25% and 30% of these players**. The high concentration of skills centers (the Medicen and System@tic clusters, the haute école elite engineering schools, the universities, the national research institutes, etc.) and the interactions between them make the Essonne one of France’s key innovation centers.

*source: Paris Region Economic Development Agency - ** source: Essonne County Economic Development Agency

GENOPOLE® - AN ACTIVE MEMBER OF THE MEDICEN PARIS REGION CLUSTER

Medicen Paris Region is a world-class cluster that proactively federates businesses, national research institutes, higher education institutions and local authorities around a common goal: reinforcing the competitiveness, visibility and attractiveness of Paris and its region in the life sciences, healthcare technology and pharmaceuticals. Medicen Paris Region covers 6 themes: neurosciences, oncology, infectious disease, biomedical imaging, molecular & cellular medicine and pharmaceutical science & technology.

Thanks to dynamic collaboration, networking and the implementation of major common-interest projects for healthcare stakeholders in the Paris Ile-de-France Region, the cluster is promoting work on these 6 themes. The goal is to build a true cluster by increasing efficiency, competitiveness, innovation, media visibility and national & international attractiveness. Being based in the Paris Ile-de-France region must become a key success factor for healthcare and pharmaceutical companies, be they start-ups or multinationals!

Genopole® is a founding member of Medicen Paris Region (currently chaired by Emmanuel Canet) and Genopole CEO Pierre Tambourin serves as the cluster’s Vice Chairman.
2008 was a particularly important year for biomanufacturing at Genopole®. Firstly, the installations and operating procedures at the recently created GMP Biomanufacturing Center for therapeutic proteins were qualified. Secondly, feasibility and construction planning studies were carried out for Genethon’s Gamma project on the GMP production of clinical trial batches of viral vectors and plasmids. The ambition is to turn Genopole® into a French and international center of excellence in biomanufacturing by offering several production technologies and a complete range of custom services in this field, ranging from gene synthesis through to clinical trials: design and construction of the optimal expression system for a molecule of interest, a pre-GMP pilot trial, GMP production, batch release and both inline & post-production analytical & virological quality controls.

Biomanufacturing projects:

Projects underway:
- a GMP biomanufacturing center for clinical batches of recombinant proteins and monoclonal antibodies produced in animal cells.
- a new Genethon unit for the GMP production of clinical batches of viral vectors.
- a biomanufacturing center for pre-industrial-scale batches of enzymes and biocatalysis products.

Projects in the planning stages:
- a pre-GMP pilot cell engineering laboratory.
- a GMP facility for production of therapeutic proteins in yeasts and bacteria.
- a GMP unit for the production of vaccine proteins in plant-based systems.
- a custom aseptic dispensing unit.
- a bioprocess research institute and collaboration on a specific training program on GMP biomanufacturing.

Lastly, two Genopole® companies are developing innovative projects for transforming green waste into energy.

Shared skills

Initiated by Genopole®, this activity is now performed by the BioSupport employers’ group, in which 24 companies share «standard» skills such as an Administrative and Financial Director, administrative assistance and (as of 2008) quality assurance and IT maintenance services.

Shared services

Genopole® is progressively setting up a range of services for campus organizations and their employees.

- **IT services** that meet the biopark companies’ needs.
  Since September 2008, these services have enabled biopark-based members to optimize and secure their IT environments: access to a high-speed fiber optic network, secure back-ups, web and e-mail server hosting and management in a dedicated machine room, VPN access, activity continuity planning, update management and antivirus protection.

- **electronic access to journals and databases**: in 2006, Genopole® gave its members trial electronic access to 1,676 scientific journals and scientific & business databases.

- **improving life on campus**: an intercompany committee for social, cultural and sporting activities, a staff restaurant, a kindergarten, etc.

Furthermore, the not-for-profit organization Science Accueil has been running a relocation office at the University of Evry-Val d’Essonne since September 2008. The goal is to facilitate the arrival of visiting researchers, lecturers and PhD students from abroad or from other parts of France by providing help with administrative matters, language courses, finding accommodation and schools, etc.).

The Institute for Systems & Synthetic Biology (ISSB)

In view of the growing success of the Epigenomics Program, the creation of an Institute for Systems and Synthetic Biology (in consultation with the CNRS and the UEVE) has been suggested. The Institute will feature both “dry” and “wet” labs in order to firmly link modeling to experimental results.
Construction of the UEVE Institute of Biology started in September 2009 and is due to be deployed in two phases.

The Institute will federate the biopark’s life science research strengths and will help create an internationally renowned teaching cluster.

The first phase (with 7,204 m² of floor space) will open in 2011 and will host a good proportion of the bioinformatics and biomathematics researchers, together with teaching facilities for the Masters courses in biology linked to ongoing research at Genopole®. A second phase will open in 2014 and will host many of the biopark’s remaining labs.

From the bench to the bedside: the objective of the future Clinical and Translational Research Center (CRCT) is to rapidly transform research results into innovative medical treatments.

Located on a 10-hectare plot at the border between the towns of Corbeil-Essonnes and Evry, the South Ille-de-France Medical Center (CHSF) will feature 37 wards, 20 operating theaters and 130 consultation rooms. The CHSF’s cornerstone was laid on July 10, 2007, by Roselyne Bachelot, France’s Minister for Health, Youth and Sports. The medical center and the CRCT are due to open in May 2011.

A biotherapy institute is being planned, in collaboration with the AFM and the INSERM; the goal will be to bring together the biopark’s research skills in the stem cell, gene therapy and cell therapy fields.

The conclusions of a Europe-wide market/user survey performed in 2007 and 2008 indicate that, there will be enough demand in 2010 to justify the creation of a small-animal in vivo imaging centre at Genopole®. The center will operate in close collaboration with the CEA’s existing MIRCEN and Neurospin centers.
The Genopole® teams’ core activities include:

- building and coordinating a research cluster in genomics, post-genomics and related sciences.
- reinforce a life science teaching and training cluster, in collaboration with the UEVE.
- promoting the growth of biotech via start-up, business development and relocation support.
- promoting the biopark and its stakeholders in France and worldwide.
- increasing the public understanding of science and contributing to societal debate on issues in genetics research and biotech.
MAIN MISSIONS: reinforcing the biopark’s research strengths, structuring and coordinating scientific life within the cluster and contributing to the development of new academic sectors and the constitution of joint research units.

Genopole® provides research groups and researchers with optimal conditions for setting up on campus, developing their research and exploiting the results. Our dedicated Genopole® Research team helps researchers move into functional, customized lab space and can provide support and funding for taking on staff and buying equipment, as well as access to a range of shared-access facilities and a high-quality program of scientific events.

Thanks to a range of activities and tools (research group establishment grants, visiting fellowships for foreign scientists, «reverse brain drain» grants, etc.), Genopole® is reinforcing the campus’s skills and research strengths.

THE GENOPOLE® RESEARCH TEAM

- implements a pro-active policy for attracting top-class researchers and research groups from elsewhere in France and abroad.

- helps new laboratories set up on campus and part-funds high-potential research programs on stem cells, biotherapies, systems & synthetic biology, proteomics, metabolomics, biomaterials, etc.

- contributes to the emergence of tomorrow’s leading scientists: the Genopole® ATIGE Research Group Establishment Grants offer present or future staff researchers an opportunity to found and lead a research group in a research institute or university lab based on the Genopole® campus. An ATIGE grant is worth €76,000 a year for 3 years. Since 2001, Genopole® has awarded 18 ATIGE grants.

- encourages expat researchers to return to France: Genopole® awards grants to young, French-trained scientists who wish to return to France after having performed postdoctoral research abroad. The two-year grant enables holders to:
  - set up and run a research project within a campus lab or company.
  - look for a permanent job.

Since the start of the program, 56 postdoc researchers have each received €55,000 a year for 2 years: all have gone on to find a job in academia or industry.

- coordinates scientific events with biopark stakeholders and their off-campus partners by promoting interdisciplinarity and mutual knowledge of research activities (notably for PhD students and postdocs). Genopole® Research helps organize a rich program of scientific events and meetings. It provides support to many campus seminars and high-level teaching & training activities, either on its own initiative or as a result of suggestions from Genopole® labs: summer schools, multidisciplinary workshops, think tanks, colloquia, symposiums, joint clinical & fundamental research days and much more.

- contributes to the development of new academic fields, the constitution of joint national research institute/University units and the creation of the Institute of Biology, in collaboration with the University of Evry-Val d’Essonne.
Genopole® Enterprises

Genopole® was designed to promote the creation, establishment and development of biotech companies in order to transform the results of life science research into drugs or industrial products, build a truly world-class biopark and contribute to the success of French biotechnology.

Personalized Project Support

The Genopole® Enterprises team is made up of experienced project managers with complementary backgrounds. It covers all the operational phases in business creation and development. From the birth of an idea in the lab through to market validation, Genopole® provides budding or experienced entrepreneurs with scientific, managerial, logistic and financial assistance, in close collaboration with other business support organizations and the financial community.

A committee of independent experts helps the Genopole® Enterprises team evaluate and refine business plans. Genopole® portfolio companies and entrepreneurs are also eligible to receive pre-seed finance from the G1J Ile-de-France fund.

Genopole® Enterprises is active in 4 areas:

- helping entrepreneurs to transform their ideas into market-valued companies: fundraising, industrial alliances and turnover generation.
- encouraging existing companies to move onto the top-class Genopole® campus.
- promoting the development of Genopole® portfolio companies: winning international business, in- and outlicensing operations, product and service commercialization, etc.
- on-site networking, with monthly business clubs for promoting dialogue on key corporate issues.

Accreditation: a sign of excellence

Before receiving financial and project support from Genopole®, each candidate for business incubation is evaluated by Genopole® Enterprises and undergoes validation by a committee of independent experts in business, finance and science. Accredited companies obtain full access to Genopole® services and a special network of business development partners. Established companies wishing to benefit from preferential access to the biopark’s environment and facilities can also apply to the Genopole® Executive Board for accreditation.

Since 1998, Genopole® has created and/or hosted over 100 biotech companies. At the end of 2008 the Genopole® Enterprises portfolio stood at 69 businesses – a true success in terms of value creation.
Providing biotech companies with early-stage funding

G1J Ile-de-France is a biotech-dedicated, pre-seed fund that has been set up in collaboration with France’s Caisse des Dépôts et Consignations state savings and investment bank. Over the period 2000-2008, the fund invested €1.55 million in Genopole® portfolio start-ups and has helped to leverage investment of €125 million in 17 companies (from seed funding through to Series D financing).

Since mid-2008 (and an additional €5 million round of fundraising), the G1J Ile-de-France has extended its activity to early-stage investment in innovative companies through the Paris Ile-de-France region.

G1J Ile-de-France works hand-in-hand with all the region’s company incubators to promote the emergence of promising projects which, thanks to early-stage funding and support, will be able to attract investors at the various steps in corporate life.

G1J Ile-de-France can invest up to €300,000 per company (in equity and/or as share warrants).

G1J Ile-de-France’s Shareholders
- CDC Enterprises FPMEI & FFI-B
- The Ile-de-France Regional Council
- MGÉN
- Groupe industriel Marcel Dassault (GIMD)
- Banque Populaire Rives de Paris
- Société Générale/Franpart
- Association française contre les myopathies (AFM)
- Merck Serono Biodevelopment
- Crédit Agricole Ile-de-France
- Société Générale de financement du Québec
- Fonds des travailleurs québécois (FTQ)
- Essonne Chamber of Commerce & Industry (CCIE)
- Crédit Agricole Capital Investissement & Finance
- Biogemma
- Matignon Développement 3
- Laboratoires Servier
- Accor
- IBM
- Safidi/Groupe EDF
- Agro Partenaires Participations 2
A SPECIFIC SERVICE for companies based in the Paris Ile-de-France region

The European Union fosters economic growth, innovation and R&D via a number of collaborative programs.

The 7th RTD Framework Programme (FP7) is the European Commission’s main tool for funding research and innovation. Fifteen percent of the overall €50 billion budget is earmarked for SMEs.

In order to facilitate and promote the participation of innovative Paris Ile-de-France region biotech companies in FP7 programs, the Genopole®-Medicen European Office was created in 2007; it advises Genopole® and Medicen Paris Region cluster companies on winning European funding.

The European Office’s activities are primarily related to:

- **the provision of information** on calls for proposals for SMEs keen to build, lead and exploit collaborative projects. This mainly covers the latest news on European and transnational programs.

- **partner searching**: the Genopole®-Medicen European Office has access to a Europe-wide network, notably via its intercluster collaborations.

- **detailed knowledge** of how European institutions operate.

- **analysis of a project’s feasibility**: identification of a call for proposals that corresponds to the project’s objectives and provision of strategic advice on putting a proposal together.

- **proposal writing support**: written contributions to and validation of the scientific and administrative sections.

- **project negotiation and operational management**.
Genopole®
GLOBAL INFRASTRUCTURE AND PLATFORMS

SHARING infrastructure, expertise, skills and resources

The mission of the «Global Infrastructure and Platforms» department is to provide the biopark’s scientific and industrial community with high-performance research infrastructures which they could not purchase alone.

By responding to stakeholder needs and thus improving the campus’s attractiveness and image, Genopole®’s dedicated infrastructure team:

- manages the creation of shared-access platforms and services, from identifying needs to on-site commissioning.

- sets and monitors criteria in terms of the accessibility, marketing and quality of the facilities and checks that the latter are self-financing.

- monitors and optimizes the facilities’ operational quality.

- coordinates measures for increasing use of the various platforms.

- establishes true networks between companies and laboratories, with a view to boosting competitiveness and increasing the efficiency of technology transfer.

- provides shared access to semi-heavy equipment.

The «Global Infrastructure and Platforms» department fosters the sharing of existing Genopole®-based equipment (notably in terms of availability) and promotes innovation in technology transfer and industrial development on the regional level.

The department now oversees 19 shared-access platforms and facilities.
GENOPOLE® INTERNATIONAL’S PRIME MISSIONS ARE (i) PROMOTING GENOPOLE®’S STRENGTHS TO THE international biopharmaceutical industry and foreign research organizations, investors and bio-incubators and (ii) helping the biopark’s companies to develop their international business activities effectively.

Thanks to the quality of its research expertise and infrastructure and the dynamism of its life science businesses, French biotech industry is now ranked 3rd in Europe. Genopole® has contributed significantly to this success by implementing an increasing number of initiatives for exporting its member’s skills and facilitating the international business development of its portfolio companies.

The team’s many links with biotech players worldwide enable it to identify new collaborative partners and help reinforce the biopark’s attractiveness.

Genopole® International (in close collaboration with the Medicen Paris Region cluster, BioTeam Paris Region, the Essonne Economic Development Agency, the Essonne Chamber of Commerce & Industry and the Paris Region Economic Development Agency (ARD)) has four major activities:

1\ Business development
- assisting start-ups to develop their business internationally.
- helping companies identify and implement international collaborations (in conjunction with Genopole® Enterprises, Genopole® Research and Genopole® Communication) by attending the sector’s major events: BIO, BioMed, BioSquare, BioVision, EuroBIO, BioJapan, BioForum Shanghai, etc.

2\ Marketing the biopark
- raising awareness of Genopole® members with the international biopharmaceutical industry and foreign research organizations, investors and bioincubators.
- consolidating existing relationships and collaborations.

3\ Becoming a player in European Research Area
- promoting the services of the Genopole®-Medicen European Office, whose mission is to help start-ups access European programs and funding.
- coordinating or participating in European projects: NATIBS, BioLink and (most recently) Bio-CT - a multicluster project which seeks to pool tools and expertise in technology platform management, the “reverse brain drain” and the maturation of innovative life science start-ups.

4\ Leveraging skills
- encouraging French-trained expat researchers or entrepreneurs to return to France.
- hosting world-class scientists and businesspeople working on specific programs.
CONTRIBUTING to the cluster’s national and international prestige and leveraging the know-how and skills of Genopole® and its partners.

Thanks to the excellent results obtained over the last 11 years, Genopole® has achieved a high level of visibility and forged an outstanding reputation - making it a benchmark biopark in France and in Europe as a whole.

In general, economic development and value creation in the hi-tech sector have been catalyzed in great part by the establishment and development of large clusters.

Several countries (notably emerging ones) are now seeking to develop this concept in the biotech field and are relying on the expertise of trend-setting developed countries such as the United States and the United Kingdom but also France, with its Genopole® model.

In this respect, Genopole® has been contacted by several countries wishing to establish collaborations or contracts for the development of bioparks and/or life science clusters.

This high level of interest in forging international collaborations has prompted the creation of Genopole®’s «Cluster Engineering» team, with a view to responding adequately and effectively to requests from abroad.

As a result of this significant interest, Genopole® has set up agreements with the following countries:

**South Africa**

South Africa was the first country to initiate an international collaboration with Genopole®. The French cluster hosted and trained a manager from Pretoria’s biopark.

This collaboration is still being run by Genopole® Enterprises in response to a request from the Ile-de-France Regional Council. The current phase consists in analyzing the feasibility of some South African life science business plans relative to Genopole®’s established criteria.

**Saudi Arabia**

On March 25th, 2008, and under the auspices of the French Ministry for Research and Higher Education, Genopole® signed cooperation contracts with two Saudi Arabian universities. The agreements formed part of an umbrella agreement signed by French President Nicolas Sarkozy during his visit to Saudi Arabia in January 2008. The two countries intend to develop academic and research-based collaborations and to exchange expertise.

**Poland**

On July 4th, 2008 Genopole® signed a memorandum of understanding with the LifeScience Cluster at the Jagiellonian University in Krakow. The memorandum covers development support for the Polish cluster, notably in terms of building infrastructure projects and seed funds.

Genopole® is currently elaborating international collaborations with other countries, such as Tunisia and the Congo.
PROMOTING AND ADDING VALUE to biopark and stakeholders on one hand and contributing to better understanding of the new ethical and societal issues raised by progress in genetics on the other.

In order to underpin the reputations of the biopark and its stakeholders and raise their respective profiles, the Genopole® Communication team generates promotional material, organizes scientific and corporate events and regularly offers Genopole® members the opportunity to attend key biotech events.

The Communication team’s missions are as follows:

- RAISING GENOPOLE®’S PROFILE AND MARKETING ITS MEMBERS’ ACTIVITIES
  - reinforcing the attractiveness of the biopark for researchers, entrepreneurs and investors.
  - organizing the attendance of biopark companies and labs at major national and international events in healthcare and biotech (BIO, EuroBiO, etc.): booking, exhibition stand management and creation of individual marketing material, etc.
  - media coverage: drafting and circulation of press releases and the organization of press conferences on behalf of Genopole®-accredited labs and companies.
  - marketing material: brochures, annual reports, directories, posters, corporate videos, diagrams and maps, websites, newsletters, etc.
  - dedicated events (inaugurations, open days, etc.) and promotion of the seminars, colloquia and other meetings organized on the biopark.
  - crisis communication: companies and laboratories confronted with a crisis situation can benefit from Genopole® Communication’s expertise in this field.

- DEVELOPING A CAMPUS CULTURE
  Our on-site activities aim at growing a sense of belonging to Genopole® and promoting dialogue between campus stakeholders. This includes:
  - running a website and an extranet.
  - organizing the «Génofolies» campus festival.
  - contributing to the «Forum» campus newsletter.

- ENABLING SOCIALLY RESPONSIBLE DIALOGUE
  Circulating scientific information to the general public and participating in societal debate on research in genetics and biotech:
  - organizing public debates on issues in life science research, such as the «Junior Gene Cafés» for junior high and high school students.
  - coordinating campus events as part of France’s annual Science Festival: open days at labs and companies, events for the general public, etc.
  - involvement in civic activities and information provision in partnership with a range of organizations: the «Knowledge Bank» with the Essonne County Council, the “Ethics Workshop” with Evry City Hall, etc.
  - support for educational initiatives, such as Genethon’s DNA School featuring science workshops for the general public and schools.
Genopole®
REAL ESTATE

A RICH, diversified real estate offering

With over 87,000 m² of floor space dedicated to research and biotech, Genopole® has a varied real estate offering that meets the specific needs of life science companies and labs. Modules from 10 m² to several thousand m² are immediately available.

Genopole® offers research groups and academic laboratories operational, fitted-out premises.

Genopole® has developed comprehensive procedures for helping companies set up on campus:
- free office space for company founders.
- France’s leading biotech-dedicated, ISO 9001-certified company incubator (run by the CCIE) hosts budding entrepreneurs at the heart of the Genopole® campus in Evry-Corbeil and offers them structured support in establishing their businesses.
- office and lab accommodation for mature companies, in collaboration with the SEM Genopole® private-public joint venture.

SEM Genopole® was founded in 2002: it builds and fits out corporate accommodation (the Genavenir buildings) which is perfectly suited to the specific needs and constraints of biotech firms:
- highly modular floor space, covering requirements from 200 m² to 3,000 m².
- complete freedom to fit out the office and lab space.
- well-equipped technical facilities in the basement.
- easy access and parking.

An exceptional reservoir of real estate opportunities:
- 8 buildings already in service (25,550 m² leased).
- 2 additional buildings scheduled for 2011-2013 (5,400 m² for lease or sale).

Facilities management:
- on-site security (closed circuit TV, security staff, etc.).
- maintenance of shared-access areas.

In the planning stages:
- management of maintenance contracts (air treatment, air conditioning, etc.).
- shared-use facilities in a single location (cold rooms, wash rooms, etc.).
- general biopark management.

The Genopole® biopark is situated in a high-quality environment with:
- landscaped parkland.
- a 700-seat international convention center (the Genocentre).
- access to an ultra-broadband network.

Lastly, the nearby Leonardo de Vinci business park (developed by the Evry Centre Essonne Metropolitan Area and the Paris Region Real Estate Authority) offers companies needing more space a range of plots (from 5,000 m² to 10 hectares) in a high-quality environment on the edge of a wooded area.

The CCIE - Genopole® Enterprise Company Incubator
Marie-Noëlle Decarreaux
Incubator Manager
mn.decarreaux@essonne.cci.fr

SEM Genopole®
Fabrice Taratte
Chief Executive
fabrice.taratte@semgenopole.fr
GENOPOLE®, THE BENCHMARK BIOPARK

Campus 1
1. Genopole Corporate HQ, Imagene, Integragen, ISSB, Sigma Aldrich, Serial Genetics, Biofords, SEM Genopole, Biomanufacturing Center, several Inserm laboratories (including I-Stem).
2. Genopole/CCIE company incubator, Genavenir office buildings, CERFE, laboratory Inserm/UEVE.
3. AFM, Génélthon, Génocentre, Genosafe.
4. The future South Île-de-France medical Center (CHSF).
5. The future Clinical and Translational Research Center (CRCT).

Campus 2
3. Genomics Institute (Genoscope and the National Genotyping Center), INRA, CEA, CNRS and UEVE labs, Sanofi Aventis Èvry Genetics Center, PartnerChip.
4. Futur Institute of Biology.
5. Epigenomics Program, Genoplante Valor.